Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: Comparison of the structural and biological properties of the three poliovirus serotypes

Structure

Volumn 5, Issue 7, 1997, Pages 961-978

  Lentz, Karen N ^a   Smith, Allen D ^a   Geisler, Sheila C ^a   Cox, Stuart ^b   Buontempo, Peter ^b   Skelton, Angela ^b   DeMartino, Jason ^b   Rozhon, Edward ^b,c   Schwartz, Jerome ^b   Girijavallabhan, V ^b   O'Connell, John ^b   Arnold, Edward ^a  

^a RUTGERS UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Shaman Pharmaceuticals Inc   (United States)

Author keywords

Crystallography; Drug design; Picornavirus; Virus assembly; Virus structure

Indexed keywords

ANIMALIA; ENTEROVIRUS; HUMAN POLIOVIRUS 2; MIRIDAE; MURINAE; PICORNAVIRIDAE; POLIOVIRUS; PRIMATES; RNA VIRUSES; THEILER'S ENCEPHALOMYELITIS VIRUS; TRIXIS;

EID: 12644284498     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-2126(97)00249-9     Document Type: Article

References (119)

1. Rueckert, R.R. (1996). Picornaviridae: the viruses and their replication. In Fields Virology. (Fields, B.N., Knipe, D.M. & Howley, P.M. eds), pp. 609-654, Lippincott-Raven, PA.
2. Melnick, J.L. (1996). Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In Fields Virology. (Relds, B.N., Knipe, D.M. & Howley, P.M. eds), pp. 655-712, Lippincott-Raven, PA.
3. Arnold, E., et al., & Wimmer, E. (1987). Implications of the picornavirus capsid structure for polyprotein processing. Proc. Natl. Acad. Sci. USA 84, 21-25.
4. Lee, W., Monroe, S.S. & Rueckert, R.R. (1993). Role of maturation cleavage in infectivity of picornaviruses: activation of an infectosome. J. Virol. 67, 2110-2122.
5. Basavappa, R., Syed, R., Flore, O., Icenogle, J.P., Filman, D.J. & Hogle, J.M. (1994). Role and mechanism of the maturation cleavage of VPO in poliovirus assembly: structure of the empty capsid assembly intermediate at 2.9 Å resolution. Protein Sci. 3, 1651-1669.
6. Harber, J.J., Bradley, J., Anderson, C.W. & Wimmer, E. (1991). Catalysis of poliovirus VPO maturation cleavage is not mediated by serine 10 of VP2. J. Virol. 65, 326-334.
7. Mendelsohn, C.L., Wimmer, E. & Racaniello, V.R. (1989). Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 56, 855-865.
8. Bernhardt, G., Harber, J., Zibert, A., deCrombrugghe, M. & Wimmer, E. (1994). The poliovirus receptor: identification of domains and amino acids residues critical for virus binding. Virology 203, 344-356.
9. Ren, R., Constantini, F., Gorgacz, E.J., Lee, J.J. & Racaniello, V.R. (1990). Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell 63, 353-362.
10. Koike, S., Taya, C., Kurata, T., Abe, S., Ise, I., Yonekawa, H. & Nomoto, A. (1991). Transgenic mice susceptible to poliovirus. Proc. Natl. Acad. Sci. USA 88, 951-955.
11. Murray, M.G., Bradley, J., Yang, X., Wimmer, E., Moss, E.G. & Racaniello, V.R. (1988). Poliovirus host range is determined by a short amino acid sequence in neutralizing antigenic site I. Science 241, 213-215.
12. Moss, E.G. & Racaniello, V.R. (1991). Host range determinants located on the interior of the poliovirus capsid. EMBO J. 10, 1067-1074.
13. Couderc, T., Hogle, J., LeBlay, H., Horaud, F. & Blondel, B. (1993). Molecular characterization of mouse-virulent poliovirus type 1 Mahoney mutants: involvement of residues of polypeptides VP1 and VP2 located on the inner surface of the capsid protein shell. J. Virol. 67, 3808-3817.
14. Couderc, T., et al., & Blondel, B. (1994). Substitutions in the capsids of poliovirus mutants selected in human neuroblastoma cells confer on the Mahoney type 1 strain a phenotype neurovirulent in mice. J. Virol. 68, 8386-8391.
15. Martin, A., Wychowski, C., Couderc, T., Crainic, R., Hogle, J. & Girard, M. (1988). Engineering a poliovirus type 2 antigenic site on a type 1 capsid results in a chimeric virus which is neurovirulent for mice. EMBO J. 7, 2839-2847.
16. Joklik, W.K. & Darnell, J.E. (1961). The absorption and early fate of purified poliovirus in HeLa cells. Virology 13, 439-447.
17. Yafal, A.G., Kaplan, G., Racaniello, V.R. & Hogle, J.M. (1993). Characterization of poliovirus conformational alteration mediated by soluble cell receptors. Virology 197, 501-505.
18. Fricks, C.E. & Hogle, J.M. (1990). Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding. J. Virol. 64, 1934-1945.
19. Racaniello, V.R. (1996). The poliovirus receptor: a hook, or an unzipper? Structure 4, 769-773.
20. McSharry, J.J., Caliguiri, L.A. & Eggers, H.J. (1979). Inhibition of uncoating of poliovirus by arildone, a new antiviral drug. Virology 97, 307-315.
21. Kuhrt, M.F., Francher, M.J., Jasty, V., Pancic, F. & Came, P.E. (1979). Preliminary studies of the mode of action of arildone, a novel antiviral agent. Antimicrob. Agents Chemother. 15, 813-819.
22. Zeichardt, H., Otto, M.J., McKinlay, M.A., Willingmann, P. & Habermehl, K.O. (1987). Inhibition of poliovirus uncoating by disoxaril (WIN 51711). Virology 160, 281-285.
23. Smith, T.J., et al., & Otto, M.J. (1986). The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science 233, 1286-1293.
24. Badger, J., et al., & Heinz, BA (1988). Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc. Natl. Acad. Sci. USA 85, 3304-3308.
25. Kim, S., et al., & McKinlay, M.A. (1989). Crystal structure of human rhinovirus serotype 1A (HRV1 ). J. Mol. Biol. 210, 91-111.
26. Zhang, A., Nanni, R.G., Oren, DA., Rozhon, E.J. & Arnold, E. (1992). Three-dimensional structure-activity relationships for antiviral agents that interact with picornavirus capsids. Semin. Virol. 3, 453-471.
27. Zhang, A., et al., & Arnold, E. (1993). Structure determination of antiviral compound SCH 38057 complexed with human rhinovirus 14. J. Mol. Biol. 230, 857-867.
28. Oliveira, M.A., et al., & Rossmann, M.G. (1993). The structure of human rhinovirus 16. Structure 1, 51-68.
29. Grant, RA., Hiremath, C.N., Filman, D.F., Syed, R., Andries, K. & Hogle, J. (1994). Structures of poliovirus complexes with antiviral drugs: implications for viral stability and drug design. Curr. Biol. 4, 784-797.
30. Muckelbauer, J.K., et al., & Rossmann, M.G. (1995). The structure of coxsackievirus B3 at 3.5 Å resolution. Structure 3, 653-667.
31. Oren, DA., Zhang, A., Nesvadba, H., Rosenwirth, B. & Arnold, E. (1996). Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061 bound to human rhinovirus 14. J. Mol. Biol. 259, 120-134.
32. Zhao, R., et al., & Rossmann, M.G. (1996). Human rhinovirus 3 at 3.0 Å resolution. Structure 4, 1205-1220.
33. Rossmann, M.G., et al., & Vriend, G. (1985). Structure of a human common cold virus and functional relationships to other picornaviruses. Nature 317, 145-153.
34. Rossmann, M.G. (1989). The canyon hypothesis: hiding the host cell receptor attachment site on a viral surface from immune surveillance. J. Biol. Chem. 264, 14587-14590.
35. Kaplan, G., Peters, D. & Racaniello, V.R. (1990). Poliovirus mutants resistant to neutralization with soluble cell receptors. Science 250, 1596-1599.
36. Olson, N.H., et al., & Rossmann, M.G. (1993). Structure of a human rhinovirus complexed with its receptor molecule. Proc. Natl. Acad. Sci. USA 90, 507-511.
37. Colston, E. & Racaniello, V.R. (1994). Soluble receptor-resistant poliovirus mutants identify surface residues and internal capsid residues that control interaction with the cell receptor. EMBO J. 13, 5855-5862.
38. Colston, E.M. & Racaniello, V.R. (1995). Poliovirus variants selected on mutant receptor-expressing cells identify capsid residues that expand receptor recognition. J. Virol. 69, 4823-4829.
39. Hogle, J.M., Chow, M. & Filman, D.J. (1985). Three-dimensional structure of poliovirus at 2.9 Å resolution. Science 229, 1358-1365.
40. Filman, D.J., Syed, R., Chow, M., Macadam, A.J., Minor, P.D. & Hogle, J.M. (1989). Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. EMBO J. 8, 1557-1579.
41. Smyth, M., Tate, J., Hoey, E., Lyons, C., Martin, S. & Stuart, D. (1995). Implications for viral uncoating from the structure of bovine enterovirus. Nat. Struct. Biol. 2, 224-231.
42. Smith, T.J., Chase, E.S., Schmidt, T.J., Olson, N.H. & Baker, T.S. (1996). Neutralizing antibody to human rhinovirus 14 penetrates the receptor-binding canyon. Nature 383, 350-354.
43. Buontempo, P.J., et al., & O'Connell, J.F. (1997). SCH48973: a potent, broad spectrum, anti-enterovirus compound. Antimicrob. Agents Chemother. 41, 1220-1225.
44. Girijavallabhan, V., Ganguly, R. & Versace, R. (1995). US Patent No. 5,350,772.
45. Cox, S., et al., & O'Connell, J.F. (1996). Antipicornavirus activity of SCH 47802 and analogues: in vitro and in vivo studies. Antiviral Res. 32, 71-79.
46. Rozhon, E., et al., & Girijavallabhan, V. (1993). SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating. Antiviral Res. 21, 15-35.
47. Palmenberg, A.C. (1989). Sequence alignments of picornaviral capsid proteins. In Molecular Aspects of Picornavirus Infection and Detection. (Semler, B.L. & Ehrenfeld, E. eds), pp. 211-241, American Society for Microbiology, Washington, D.C.
48. Minor, P.D., Ferguson, M., Evans, D.M., Almond, J.W. & Icenogle, J.P. (1986). Antigenic structure of polioviruses of serotypes 1, 2, and 3. J. Gen. Virol. 67, 1283-1291.
49. Page, G.S., Mosser, A.G., Hogle, J.M., Filman, D.J., Rueckert, R.R. & Chow, M. (1988). Three-dimensional structure of poliovirus serotype 1 neutralizing determinants. J. Virol. 62, 1781-1794.
50. Hogle, J.M. & Filman, D.J. (1989). The antigenic structure of poliovirus. Phil. Trans. R. Soc. Lond. B 323, 467-478.
51. Lea, S., et al., & Mateau, M.G. (1994). The structure and antigenicity of a type C foot-and-mouth disease virus. Structure 2, 123-139.
52. Burke, K.L., Dunn, G., Ferguson, M., Minor, P. & Almond, J.W. (1988). Antigen chimeras of poliovirus as potential vaccines. Nature 332, 81-82.
53. Murray, M.G., Kuhn, R.J., Arita, M., Kawamura, N., Nomoto, A. & Wimmer, E. (1988). Poliovirus type1/type 3 antigenic hybrid virus constructed in vitro elicits type 1 and type 3 neutralizing antibodies in rabbits and monkeys. Proc. Natl. Acad. Sci. USA 85, 3203-3207.
54. Murdin, A.D. & Wimmer, E. (1989). Construction of a poliovirus type1/type 2 antigenic hybrid by manipulation of neutralization antigenic site II. J. Virol. 63, 5251-5257.
55. Murdin, A.D., Lu, H., Murray, M.G. & Wimmer, E. (1992). Poliovirus antigenic hybrids simultaneously expressing antigenic determinants from all three serotypes. J. Gen. Virol. 73, 607-611.
56. Smith, A.D., Resnick, D.A., Zhang, A., Geisler, S.C., Arnold, E. & Arnold, G.F. (1994). Use of random systematic mutagenesis to generate viable human rhinovirus 14 chimeras displaying human immunodeficiency virus type 1 V3 loop sequences. J. Virol. 68, 575-579.
57. Lomonossoff, G.P. & Johnson, J.E. (1996). Use of macromolecular assemblies as expression systems for peptides and synthetic vaccines. Curr. Opin. Struct. Biol. 6, 176-182.
58. Andries, K., et al., & Janssen, P.A.J. (1990). Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity. J. Virol. 64, 1117-1123.
59. Mian, I.S., Bradwell, A.R. & Olson, A.J. (1991). Structure, function, and properties of antibody binding sites. J. Mol. Biol. 217, 133-151.
60. Nanni, R.G., Ding, J., Jacobo-Molina, A., Hughes, S.H. & Arnold, E. (1993). Review of HIV-1 reverse transcriptase three-dimensional structure: implications for drug design. Drug Disc. Des. 1, 129-150.
61. Janin, J. & Chothia, C. (1990). The structure of protein-protein recognition sites. J. Biol. Chem. 265, 16027-16030.
62. Wilson, I.A. & Stanfield, R.L. (1993). Antibody-antigen interactions. Curr. Opin. Struct. Biol. 3, 113-118.
63. Robinson, I.K. & Harrison, S.C. (1982). Structure of the expanded state of tomato bushy stunt virus. Nature 297, 563-568.
64. Godfrey, J.C. (1988). Zinc for the common cold. Antimicrob. Agents Chemother. 32, 20-24.
65. McKenna, R. & Incardona, N.L. (1992). Atomic structure of single-stranded DNA bacteriophage •X174 and its functional implications. Nature 355, 137-143.
66. Godfrey, J.C., Conant-Sloane, B., Smith, D.S., Turco, J.H., Mercer, N. & Godfrey, N.J. (1992). Zinc gluconate and the common cold: a controlled clinical study. J. Int. Med. Res. 20, 234-246.
67. Speir, J.A., Munshi, S.,Wang, G., Baker, T.S. & Johnson, J.E. (1995). Structures of the native and swollen forms of cowpea chlorotic mottle virus determined by X-ray crystallography and cryo-electron microscopy. Structure 3, 63-78.
68. Irurzun, I., Arroyo, J., Alvarez, A. & Carrasco, L. (1995). Enhanced intracellular calcium concentration during poliovirus infection. J. Virol. 69, 5142-5146.
69. McPhalen, C.A., Strynadka, N.C. & James, M.N.G. (1991). Calcium-binding sites in proteins: a structural perspective. Adv. Protein Chem. 42, 77-144.
70. Zhao, R., Hadfield, AT., Kremer, M.J. & Rossmann, M.G. (1997). Cations in human rhinoviruses. Virology 227, 13-23.
71. Chow, M., Newman, J.F.E., Filman, D., Hogle, J.M., Rowlands, D.J. & Brown, F. (1987). Myristylation of picornavirus capsid protein VP4 and its structural significance. Nature 327, 482-486.
72. Moscufo, N. & Chow, M. (1992). Myristate-protein interactions in poliovirus: interactions of VP4 threonine 28 contribute to the structural conformation of assembly intermediates and the stability of the assembled virions. J. Virol. 66, 6849-6857.
73. Arnold, E. & Rossmann, M.G. (1988). The use of molecular-replacement phases for the refinement of the human rhinovirus 14 structure. Acta Cryst. A 44, 270-282.
74. Hadfield, AT., et al., & Rossmann, M.G. (1997). The refined structure of human rhinovirus 16 at 2.15 Å resolution: implications for the viral life cycle. Structure 5, 427-441.
75. Nugent, C. & Kirkegaard, K. (1995). RNA binding properties of poliovirus subviral particles. J. Virol. 69, 13-22.
76. Ansardi, D., Luo, M. & Morrow, C. (1994). Mutations in the poliovirus P1 capsid precursor at arginine residues VP4-ARG34, VP3-ARG223, VP1-ARG129 affect virus assembly and encapsidation of genomic RNA. Virology 199, 20-34.
77. Kersten, G.F.A., Lantinga, M., Hazendonk, T. & Beuvery, E.C. (1995). Immunogenicity of trypsin treated type 2 and type 3 poliovirus in rats. Biologicals 23, 179-183.
78. Martin, A., et al., & Girard, M. (1991). Use of type1/type2 chimeric polioviruses to study determinants of poliovirus type 1 neurovirulence in a mouse model. Virology 180, 648-658.
79. Yeates, T.O., et al., & Hogle, J.M. (1991). Three-dimensional structure of a mouse adapted type1/type2 poliovirus chimera. EMBO J. 9, 2331-2341.
80. Wien, M.W., et al., & Hogle, J.M. (1995). Structure of the complex between the Fab fragment of a neutralizing antibody for type I poliovirus and its viral epitope. Nat. Struct. Biol. 2, 232-243.
81. Lecroisey, A., Martineau, P., Hofnung, M. & Delepierre, M. (1997). NMR studies on the flexibility of the poliovirus C3 linear epitope inserted into different sites of the maltose-binding protein. J. Biol. Chem. 272, 362-368.
82. Icenogle, J., Minor, P.D., Ferguson, M. & Hogle, J.M. (1986). Modulation of humoral response to a 12 amino-acid site on the poliovirus virion. J. Virol. 60, 297-301.
83. Crowell, R.L. (1966). Specific cell-surface alteration by enteroviruses as reflected by viral-attachment interference. J. Bacteriol. 91, 198-204.
84. Holland, J.J., McLaren, J.C. & Syverton, J.T. (1959). The mammalian cell virus relationship. IV. Infection of naturally insusceptible cells with enterovirus ribonucleic acid. J. Exp. Med. 110, 65-80.
85. Shiroki, K., et al., & Nomoto, A. (1997). Host range phenotype induced by mutations in the internal ribosomal entry site of poliovirus RNA. J. Virol. 71, 1-8.
86. Morrison, M.E. & Racaniello, V.R. (1992). Molecular cloning and expression of a murine homolog of the human poliovirus receptor gene. J. Virol. 66, 2807-2813.
87. Harber, J., Bernhardt, G., Lu, H.H., Sgro, J.Y. & Wimmer, E. (1995). Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of poliovirus to mutants of the poliovirus receptor. Virology 214, 559-570.
88. Acharya, R., Fry, E., Stuart, D., Fox, G., Rowlands, D. & Brown, F. (1989). The three-dimensional structure of foot-and-mouth disease virus at 2.9 Å resolution. Nature 337, 709-716.
89. Javaherian, K., et al., & Matthews, T.J. (1990). Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 250, 1590-1593.
90. Hwang, S.S., Boyle, T.J., Lyerly, H.K. & Cullen, B.R. (1991). Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253, 71-74.
91. Domingo, E., et al., & Mateu, M.G. (1993). New observations on antigenic diversification of RNA viruses. Antigenic variation is not dependent on immune selection. J. Gen. Virol. 74, 2039-2045.
92. Fricks, C., Icenogle, J. & Hogle, J.M. (1985). Trypsin sensitivity of the Sabin strain of type 1 poliovirus: trypsin cleavage sites in virus and related antigens. J. Virol. 54, 856-859.
93. Couderc, T., Martin, A., Wychowski, C., Girard, M., Horaud, F. & Crainic, L. (1991). Analysis of neutralization-escape mutants selected from a mouse virulent type 1/type 2 chimeric poliovirus: identification of a type 1 poliovirus with antigenic site 1 deleted. J. Gen. Virol. 72, 973-977.
94. Evans, D.J., et al., & Almond, J.W. (1989). An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature 339, 385-388.
95. Jenkins, O., et al., & Almond, J.W. (1990). An antigen chimera of poliovirus induces antibodies against human papillomavirus type 16. J. Virol. 64, 1201-1206.
96. La Monica, N., Kupsky, W.J. & Racaniello, V.R. (1987). Reduced mouse neurovirulence of poliovirus type 2 Lansing antigenic variants selected with monoclonal antibodies. Virology 161, 429-437.
97. Curry, S., et al., & Stuart, D. (1995). Perturbations in the surface structure of A22 Iraq foot-and-mouth disease virus accompanying coupled changes in host cell specificity and antigenicity. Structure 4, 135-145.
98. Ren, R., Moss, E.G. & Racaniello, V.R. (1991). Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J. Virol. 65, 1377-1382.
99. Taffs, R.E., et al., & Lenvenbook, I.S. (1995). Genetic stability and mutant selection in Sabin 2 strain of oral poliovirus vaccine grown under different conditions. Virology 209, 366-373.
100. Flore, O., Fricks, C.E., Filman, D.J. & Hogle, J.M. (1990). Conformational changes in poliovirus assembly and cell entry. Semin. Virol. 1, 429-438.
101. Kalko, S.G., Cachau, R.E. & Silva, A.M. (1992). Ion channels in icosahedral virus: a comparative analysis of the structures and binding sites at their fivefold axes. Biophys. J. 63, 1133-1145.
102. Tosteson, M.T. & Chow, M. (1997). Characterization of the ion channels formed by poliovirus in planar lipid membranes. J. Virol. 71, 507-511.
103. Couderc, T., Delpeyroux, F., LeBlay, H. & Blondel, B. (1996). Mouse adaptation determinants of poliovirus Type 1 enhance viral uncoating. J. Virol. 70, 305-312.
104. Giranda, V.L., Heinz, B.A. & Oliveira, M.A. (1992). Acid-induced structural changes in human rhinovirus 14: possible role in uncoating. Proc. Natl. Acad. Sci. USA 89, 10213-10217.
105. La Monica, N., Meriam, C. & Racaniello, V.R. (1986). Mapping of sequences required for mouse neurovirulence of poliovirus type 2 Lansing. J. Virol. 57, 515-525.
106. Otwinowski, Z. (1993). Oscillation data reduction program. In Proceedings of the CCP4 Study Weekend. SERC Daresbury Laboratory, Warrington, UK.
107. Matthews, B.W. (1985). Determination of protein molecular weight, hydration, and packing from crystal density. In Methods in Enzymology. (Wyckoff, H.W., Hirs, C.H.W. & Timasheff, S.N., eds), pp. 176-187, Academic Press, Orlando.
108. Tong, L. & Rossmann, M.G. (1990). The locked rotation function. Acta Cryst. A 46, 783-792.
109. Brünger, A.T. (1993). X-PLOR Manual Version 3.1: A System for X-ray Crystallography and NMR. Yale University Press, New Haven, CT.
110. Kleywegt, G.T. & Jones, T.A. (1994). Halloween...masks and bones. Proceeding of the CCP4 Study Weekend. Daresbury Laboratory, Warrington, UK.
111. Jones, T.A., Zou, J.Y., Cowan, S.W. & Kjeldgaard, M. (1991). Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Cryst. A 47, 110-119.
112. Engh, R.A. & Huber, R. (1991). Accurate bond and angle parameters for X-ray protein structure refinement. Acta Cryst. A 47, 392-400.
113. Kleywegt, G.J. & Jones, T.A. (1994). XPLO2D. Uppsala, Sweden.
114. Chapman, M.S. & Rossmann, M.G. (1996). Structural refinement of the DNA-containing capsid of canine parvovirus using RSRef, a resolution dependent stereochemically restrained real-space refinement method. Acta Cryst. D 52, 129-140.
115. Brünger, A.T. (1993). Assessment of phase accuracy by cross validation: the free R value. Methods and applications. Acta Cryst. D 49, 24-36.
116. Laskowski, R.A., MacArthur, M.W., Moss, D.S. & Thornton, J.M. (1993). PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Cryst. 26, 283-291.
117. Lee, B. & Richards, F.M. (1971). The interpretation of protein structures: estimation of static accessibility. J. Mol. Biol. 55, 379-400.
118. Carson, M. (1991). Ribbons 2.0. J. Appl. Cryst. 24, 958-961.
119. Nicholls, A. & Honig, B. (1991). A rapid finite difference algorithm, utilizing successive over relaxation to solve the Poisson-Bolzman equation. J. Comp. Chem. 12, 435-445.